• JULY 26, 2000

Sale of brands boosts Glaxo net

Glaxo’s net profit has more than doubled to Rs 295.2 m in the second quarter of the current year as compared to Rs 145.1 m in the corresponding quarter of last year. While other income amounted to Rs 110 m (vis-à-vis Rs 112.3 m in the last year), the company earned Rs 105 m on the sale of brands.

(Rs m) 2QFY99 2QFY01 Change
Sales 2,242 2,868 27.9%
Other Income 112 110 -2.0%
Expenditure 2,070 2,585 24.9%
Operating Profit (EBDIT) 172 283 64.2%
Operating Profit Margin (%) 7.7% 9.9%  
Interest 23 26  
Depreciation 34 38 11.8%
Profit before Tax 228 330 44.6%
Other Adjustments   105  
Tax   2  
Profit after Tax/(Loss) 228 433 89.9%
Net profit margin (%) 10.2% 11.4%  
No. of Shares (m) (eoy) 59.8 59.8  
Diluted no. of shares (m) 59.8 59.8  
Diluted Earnings per share* 15.2 28.9  

The company’s turnover has also grown by an impressive 27.92% at Rs 2867.8 m in the second quarter as against Rs 2241.8 m in the corresponding quarter of the last year. This looks impressive when justaposed against a 20% topline growth for Cipla and an 18% growth for Nicholas Piramal. The company's operating margins have also registered an impressive increase.

The stock quotes at a price of Rs 436, which implies an earnings multiple of 15 times its annualised earnings of calendar year 2000. If one were to exclude the entire Rs 105 m earned from the sale of its brands, still, Glaxo's second quarter bottomline has grown by an impressive 43% (as compared to the second quarter last year). If one were to take this into account the stock quotes at an earning multiple of 20 times.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407